P3 Health Partners Inc. (NASDAQ:PIII) Short Interest Update

P3 Health Partners Inc. (NASDAQ:PIII) was the recipient of a significant decrease in short interest in the month of May. As of May 29th, there was short interest totaling 138,133 shares, a decrease of 51.3% from the May 14th total of 283,541 shares. Approximately 2.3% of the shares of the stock are short sold. Based on an average trading volume of 1,072,122 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the company. Lake Street Capital reaffirmed a “buy” rating and issued a $14.00 price objective (up from $4.00) on shares of P3 Health Partners in a research note on Friday, May 15th. UBS Group set a $14.00 price objective on P3 Health Partners in a research note on Friday, May 15th. Weiss Ratings raised P3 Health Partners from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, May 28th. Finally, TD Cowen reissued a “hold” rating and set a $14.00 price target (up from $3.00) on shares of P3 Health Partners in a research note on Friday, May 22nd. One equities research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, P3 Health Partners presently has an average rating of “Hold” and an average price target of $14.00.

P3 Health Partners Stock Down 4.4%

P3 Health Partners stock traded down $0.54 during midday trading on Monday, reaching $11.69. 37,976 shares of the stock traded hands, compared to its average volume of 546,399. The stock’s fifty day moving average is $7.07 and its 200-day moving average is $4.56. P3 Health Partners has a 12 month low of $1.52 and a 12 month high of $16.89. The stock has a market cap of $84.64 million, a P/E ratio of -0.30 and a beta of 1.57.

P3 Health Partners (NASDAQ:PIII) last announced its quarterly earnings results on Thursday, May 14th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of ($4.85) by $5.17. P3 Health Partners had a negative return on equity of 302.33% and a negative net margin of 8.57%.The company had revenue of $386.39 million during the quarter, compared to analyst estimates of $391.45 million.

Hedge Funds Weigh In On P3 Health Partners

An institutional investor recently bought a new position in P3 Health Partners stock. Lido Advisors LLC acquired a new stake in shares of P3 Health Partners Inc. (NASDAQ:PIII) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 10,748 shares of the company’s stock, valued at approximately $33,000. Lido Advisors LLC owned 0.15% of P3 Health Partners at the end of the most recent reporting period. 7.75% of the stock is owned by institutional investors.

P3 Health Partners Company Profile

P3 Health Partners is a healthcare technology and services company that delivers data-driven solutions to support health plans in improving quality measures, risk adjustment accuracy and operational efficiency. The company’s platform integrates advanced analytics, reporting capabilities and workflow automation to help clients optimize performance across value-based care programs and regulatory requirements.

The company’s core offerings include quality measurement and reporting for HEDIS, STAR and other performance frameworks, risk adjustment coding and audit services, and population health analytics.